Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment of Diabetes After Gastric Bypass With Sitagliptin (LAF33)

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Blandine Laferrere, Columbia University
ClinicalTrials.gov Identifier:
NCT01512797
First received: January 13, 2012
Last updated: October 11, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2016
  Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)